Lactobacillus fermentum HNU312 and its application in the preparation of lipid-lowering drugs
The body weight and blood lipid levels of mice with high-fat diet were significantly reduced in vivo experiments through Lactobacillus fermentation, which solved the problem of fat accumulation caused by high-fat diets, and provided a low-cost, no side effects treatment method for hyperlipidemia.
Patent Information
- Application Number
- CN202211290156.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-21
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-10-21
AI Technical Summary
Due to the problems of obesity and metabolic syndrome caused by high-fat diet, the prior art is difficult to effectively alleviate hyperlipidemia and fat accumulation from the perspective of intestinal microbialities.
Using Lactobacillus fermentation HNU312 as a lipid-lowering drug, the effects on the weight, blood lipids, liver and adipose tissue of mice with high-fat diet were explored in vivo, which significantly slowed down weight growth, improved blood lipid levels, reduced fat accumulation, and in diet Continue to play a role after returning to normal.
Lactobacillus fermentation HNU312 significantly reduces the weight and blood lipid levels of mice with high-fat diets, reduces fat accumulation in liver and adipose tissue, improves hyperlipidemia, and provides a low-cost, no side effects treatment for hyperlipidemia.
Smart Images

Figure CN116121107B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms and relates to fermented lactobacillus HNU312 and application thereof in the preparation of lipid-lowering medicines. Background Art
[0002] Obesity caused by high-energy diets is spreading around the world, seriously endangering human health and quality of life. Among them, a high-fat diet may be one of the reasons for the rising incidence of metabolic syndrome. A high-fat diet can lead to increased levels of triglycerides (TG), total cholesterol (T-CHO), and low-density lipoprotein cholesterol (LDL-C), and decreased levels of high-density lipoprotein cholesterol (HDL-C), thus developing into chronic metabolic diseases. Intestinal microorganisms are the "second genome" of the human body and are inextricably linked to a variety of diseases. Now, more and more studies have shown the relationship between intestinal microbiota and metabolic syndrome.
[0003] Considering that the intestinal tissue selectively absorbs nutrients from the intestinal lumen and transports them to the liver through the portal circulation, the intestinal microbiome is a major factor in the metabolic activities of the liver and the whole body. And probiotics have been shown to be beneficial to health, either directly to the host or indirectly to the host by changing the diversity of the host's intestinal microbiota. This provides an opportunity for probiotic-based approaches to help alleviate metabolic syndrome. Probiotic intervention is low-cost and has no side effects, making it one of the best ways to prevent and treat obesity. At the same time, intestinal microorganisms have become an important new target for the treatment of metabolic diseases such as obesity in recent years. Summary of the invention
[0004] Based on the above, the purpose of the present invention is to provide Lactobacillus fermentum HNU312 and its use in the preparation of lipid-lowering drugs. The present invention uses Lactobacillus fermentum HNU312 as a research object and a normal diet as a control to explore the effect of Lactobacillus fermentum HNU312 on the prevention and treatment of hyperlipidemia caused by a high-fat diet in an in vivo experiment, and systematically studies the intrinsic mechanism of Lactobacillus fermentum HNU312 in alleviating high-fat diet-induced obesity from the perspective of intestinal microecology.
[0005] In order to achieve the purpose of the present invention, the technical solution adopted by the present invention is:
[0006] The present invention provides fermented Lactobacillus HNU312, which has been deposited in Guangdong Microbiological Culture Collection Center (GDMCC) on September 16, 2022, with a deposit number of GDMCC NO: 62803, and a deposit address: Guangdong Microbiological Culture Collection Center, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou City, Guangdong Province, China, taxonomic name: Limosilactobacillus leaven .
[0007] Preferably, the 16S rRNA sequence of the Lactobacillus fermentum HNU312 is as shown in SEQ ID NO:1.
[0008] The present invention also provides a lipid-lowering medicine, comprising the above-mentioned Lactobacillus fermentum HNU312.
[0009] The present invention further provides application of Lactobacillus fermentum HNU312 in preparing lipid-lowering medicines.
[0010] Preferably, the lipid-lowering drugs include drugs for preventing and treating hyperlipidemia.
[0011] More preferably, the hyperlipidemia is hyperlipidemia caused by a high-fat diet.
[0012] Preferably, the lipid-lowering drugs include drugs used to reduce body weight in humans or animals.
[0013] Preferably, the lipid-lowering drugs include drugs for lowering serum total cholesterol, serum triglycerides, and serum low-density lipoprotein in human or animal serum.
[0014] Preferably, the lipid-lowering drug includes a drug for reducing fat accumulation in liver tissue and adipose tissue caused by a high-fat diet.
[0015] The beneficial effects of the present invention are:
[0016] The present invention designed an 11-week in vivo experiment to explore the effects of Lactobacillus fermentum HNU312 on the body weight, blood lipids, liver and adipose tissue, and intestinal microorganisms of mice on a high-fat diet. The results showed that adding Lactobacillus fermentum HNU312 to a high-fat diet can significantly slow down the growth of body weight, improve the blood lipid levels of mice, and reduce the fat accumulation in liver tissue and adipose tissue caused by a high-fat diet. Moreover, after returning to a normal diet from a high-fat diet, Lactobacillus fermentum HNU312 can still play a role in reducing the body weight and blood lipid levels of mice and improving fat accumulation. In summary, the present invention reveals the improvement effect of Lactobacillus fermentum HNU312 on hyperlipidemia, which will provide support for the future development of drugs to improve hyperlipidemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Shows the changes in body weight of mice in each group in the in vivo experiment (t test, * p < 0.05, ** p < 0.01).
[0018] Figure 2 The levels of TG, T-CHO, LDL-C and LDL-C / HDL-C in the five groups of mice after 11 weeks (t test, different letters represent significant differences, p< 0.05).
[0019] Figure 3 The morphological analysis of liver tissue and epididymal adipose tissue fat in five groups of mice is shown (t-test, different letters represent significant differences, p < 0.05), including: A. liver weight, B. liver lipid droplet ratio (%), C. adipocyte size, D. Oil red O staining of liver tissue sections, E. H&E staining of epididymal adipose tissue sections. DETAILED DESCRIPTION
[0020] In order to explain the present invention more clearly, the present invention is further described in detail below in conjunction with embodiments and with reference to the accompanying drawings. It should be understood by those skilled in the art that the content described below is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.
[0021] Example
[0022] 1. Isolation, identification and screening of Lactobacillus fermentum HNU312
[0023] A strain of Lactobacillus fermentum HNU312, which was deposited in Guangdong Microbiological Culture Collection Center (GDMCC) on September 16, 2022, with a deposit number of GDMCC NO: 62803, and a deposit address of Guangdong Microbiological Culture Collection Center, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong, China, with a taxonomic name of Lactobacillus fermentum ( Limosilactobacillus fermentum ).
[0024] Lactobacillus fermentum ( Limosilactobacillus fermentum ) HNU312 was cultured on MRS agar medium at 37℃ for 24 h. The colonies were milky white, 0.1-0.2 cm in diameter, with a smooth, moist, raised surface and neat edges. They were rod-shaped when observed under an optical microscope.
[0025] Preliminary screening: This study collected 6 fermented fish tea samples and 6 fermented vegetable samples from Wuzhishan area of Hainan Province, and 4 fermented fish tea samples and 4 fermented vegetable samples from Baisha area of Hainan Province, totaling 20 fermented foods. The 10-fold dilution method was used to prepare a gradient of 10 -1 -10 -5 Sample dilution, take 10 -3 , 10 -4 , 10 -5 100 μL of each concentration gradient dilution was spread on MRS agar medium and cultured anaerobically at 37°C for 48 h. After multiple separation and purification cultures, and identification of the bacterial shape after Gram staining under a microscope, the strain samples with a single shape were retained and the samples of miscellaneous bacteria were eliminated.
[0026] Identification of isolates: DNA of isolates was extracted using the kit. PCR system and procedure were then performed to amplify the 16S rRNA gene of each sample. The amplified products were electrophoresed using 0.8% agarose gel electrophoresis. Sequencing was completed by Qingdao Pengxiang Biotechnology.
[0027] The sequences of the isolates were compared with those of NCBI, and the information of the highest query cover and identifier in the output results was selected as the identification result of the isolate at the species level.
[0028] 16S rRNA amplification primers
[0029]
[0030] According to the results of 16S rRNA gene sequencing, 60 strains of Lactobacillus were isolated from fermented fish tea and fermented vegetables. Lactiplantibacillus plantarum ) A total of 42 strains were isolated. Lactobacillus fermentum ( Limosilactobacillus fermentum ) A total of 18 strains were isolated.
[0031] Rescreening: The acid and bile resistance of the above 60 primary screening strains were tested to further screen out strains with strong tolerance. The method for determining the acid resistance of the strains is as follows: Use 1 mol / L HCl to adjust the MRS broth medium to pH 2.0 and 3.0, respectively, and inoculate the activated strains at 3% inoculation into MRS broth medium with different pH values, culture at 37°C for 4 h, and spread them on MRS agar medium after 10-fold gradient dilution, count, determine the number of live bacteria, calculate the survival rate, and set up a blank control at the same time. The results are shown in Table 1:
[0032] Table 1 Survival rate of strains at different pH
[0033]
[0034] The method for determining the bile salt tolerance of the strain is as follows: prepare MRS broth medium containing 0.3% and 0.4% ox bile salt, culture at 37°C for 4 h, spread on MRS agar medium after 10-fold gradient dilution, count, determine the number of viable bacteria, calculate the survival rate, and set up a blank control at the same time. The results are shown in Table 2:
[0035] Table 2 Survival rate of strains under different bile salt concentrations
[0036]
[0037] From the results in Tables 1 and 2, it can be seen that the survival rate of lactobacillus decreases with the decrease of pH value and the increase of bile salt concentration. In terms of acid resistance and bile salt resistance, the survival rate of Lactobacillus fermentum HNU312 strain can reach 95.61% and 98.44% in the environment of pH=2.5 and pH=3.5, and the survival rate can reach 60.33% and 60.31% at the bile salt concentration of 0.3% and 0.4%, respectively, indicating that Lactobacillus fermentum HNU312 strain has good tolerance.
[0038] 2. To investigate the effects of Lactobacillus fermentum HNU312 on body weight, blood lipids, liver and adipose tissue, and intestinal microorganisms in mice fed a high-fat diet
[0039] 1. Animal feed and formula
[0040] All animal experiments were approved by the Ethics Committee of Hainan University. Six-week-old C57BL / 6 J male mice (30 mice) were purchased from Hunan SJA Experimental Animal Co., Ltd. and housed in a specific pathogen-free environment with a 12-h day-night cycle at 22±2°C and 55%±10% relative humidity. The normal fat diet consisted of 41% corn, 26% bran, 29% soybean cake, 1% salt, 1% bone meal, 1% lysine, and 1% others. The high-fat diet consisted of 1% cholesterol, 10% egg yolk, 10% lard, 0.2% sodium cholate, and 78.8% normal fat diet. The main nutrients of the normal fat diet were: crude protein, 18%; crude fat, 4%; crude fiber, 5%; calcium, 1.0 to 1.8%; phosphorus, 0.6 to 1.2%. The main nutrients of high-fat feed are: crude protein, 17.6%; crude fat, 19.7%; crude fiber, 4%; calcium, 0.81 to 1.45%; phosphorus, 0.56 to 1.04%.
[0041] 2. In vivo experiments
[0042] Thirty 6-week-old C57BL / 6 J male mice were randomly divided into three groups after 7 days of normal diet adaptation in the laboratory environment: NFD group (normal fat diet, 6 mice); HFD group (high fat diet, 18 mice); HFD+Lf312 group (high fat diet + probiotic suspension, the probiotic suspension was 10 8CFU of fermented Lactobacillus HNU312 was resuspended in 300 μL sterile saline and administered by gavage, 6 mice). During this process, the NFD group and HFD group were given an equal amount of saline as a control. Body weight and feces were recorded and collected weekly and stored at -80°C. After 6 weeks of intervention, the mice in the HFD group were modeled as hyperlipidemia mice and randomly divided into 3 groups, namely: HFD group (high-fat diet, 6 mice); Lov treatment group (normal diet + drug suspension, the drug suspension was 5 mg / KG lovastatin resuspended in 300 μL sterile saline, administered by gavage, 6 mice); Lf312 treatment group (normal diet + probiotic suspension, the probiotic suspension was 10 8 CFU of Lactobacillus fermentum HNU312 was resuspended in 300 μL of sterile saline and administered by gavage to 6 mice. At this time, there were 5 groups of mice, and the intervention was continued for another 5 weeks, for a total of 11 weeks of in vivo experiments. On the last day of the 11th week, the mice were fasted for 16 hours and then euthanized.
[0043] 3. Liver Oil Red O Staining and Histomorphological Assessment
[0044] Fresh liver lobes from mice in each group were quickly frozen in liquid nitrogen and stored at -80 °C for future use. The slices were sliced in a -20 °C constant temperature freezer into 5 μm thick liver tissue slices. The slices were then attached to slides and dried naturally at room temperature for 0.5-1 h. They were then fixed in acetone at 4 °C for 5-10 min, dried in an oven for 20 min, washed three times with PBS, and finally incubated with 3% H2O2 for 5-10 min. Oil red O staining was then performed and counterstained with hematoxylin dye. Possible histopathological changes were observed under an upright optical microscope (Nikon, Shanghai, China), and images were collected and analyzed.
[0045] 4. Adipose tissue and morphology assessment
[0046] Epididymal fat of mice in each group was fixed in paraformaldehyde at room temperature and embedded in paraffin. 5-μm-thick adipose tissue sections were excised, dewaxed, stained with hematoxylin-eosin (H&E), dehydrated, and sealed with neutral glue. Possible histopathological changes were then observed under an upright optical microscope (Nikon, Shanghai, China), and images were collected and analyzed.
[0047] 5. Determination of blood lipid levels
[0048] Eyeball blood was collected and centrifuged at 571×g for 15 min at 4°C. Blood lipid indexes, including T-CHO, TG, HDL-C, and LDL-C, were measured using a detection kit (Nanjing Jiancheng Biotechnology Co., Ltd., China).
[0049] 6. Statistical analysis and chart construction
[0050] All statistical analyses were performed using R (version 3.6.1) software. Data are presented as mean ± standard deviation (SD). The t-test was used to determine whether there were significant differences between samples, with a p-value threshold of 0.05 (* p < 0.05, ** p The differences were considered significant when the difference was <0.01. GraphPad Prism 8 was used for plotting.
[0051] 7. Results
[0052] a. Lactobacillus fermentum HNU312 reduced the body weight of mice fed a high-fat diet
[0053] In vivo experiments in mice, the results were as follows Figure 1 As shown. By the 6th week, the body weight of mice in the HFD group (28.28±1.56 g) was significantly different from that in the NFD group (25.89±0.97 g). At the same time, there were significant differences between the mice in the HFD group and the HFD+Lf312 group. This shows that adding Lactobacillus fermentum HNU312 to a high-fat diet can significantly slow down the weight gain of mice. After 11 weeks, the body weight of mice in the HFD group (30.33±1.97 g) was still significantly higher than that in the NFD group (27.51±0.84 g) and the HFD+Lf312 group (28.94±0.95 g). And there was no significant difference in the body weight of mice in the NFD group and the HFD+Lf312 group. On the other hand, the mice in the Lov and Lf312 treatment groups ended the 6-week high-fat diet and were given a 5-week normal fat diet and probiotic or drug intervention (Lov treatment group: normal diet + lovastatin; Lf312 treatment group: normal diet + Lactobacillus fermentum HNU312). The results showed that there was a significant difference between the Lov treatment group (28.42±1.85 g) and the HFD group (30.33±1.97 g). In addition, there was no significant difference between the Lf312 treatment group (28.99±1.96 g) and the Lov treatment group. These results indicate that Lactobacillus fermentum HNU312 can significantly slow down the gain of body weight under high-fat diet conditions, and after returning to a normal diet from a high-fat diet, Lactobacillus fermentum HNU312 is still effective in reducing the weight of mice.
[0054] b. Lactobacillus fermentum HNU312 improved the blood lipid levels of mice fed a high-fat diet
[0055] When obesity occurs, the body's lipid metabolism is disordered and the lipid level in the blood is prone to rise. It has been shown that a long-term high-fat diet affects the levels of triglycerides (TG), total cholesterol (T-CHO), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in mouse serum. Increased LDL-C in the blood can lead to cardiovascular diseases such as atherosclerosis, and the ratio of LDL-C to HDL-C is an indicator used clinically to assess the risk of cardiovascular disease. The results showed that after 11 weeks of high-fat diet, the levels of triglycerides (TG), total cholesterol (T-CHO) and low-density lipoprotein cholesterol (LDL-C) in the serum of mice in the HFD group were significantly higher than those in other groups. The TG and LDL-C contents of the HFD+Lf312 group were not significantly different from those of the NFD group, and were both at normal levels. And its total cholesterol (T-CHO) content was also significantly lower than that of mice in the HFD group. In addition, the blood lipid levels of the Lov treatment group were not significantly different from those of the NFD group, and all returned to normal levels. In the Lf312 treatment group, T-CHO and LDL-C in their blood also dropped to normal values, and the TG content was not significantly different from that in the Lov treatment group, although it did not drop to normal levels. It is worth noting that the results showed that the LDL-C / HDL-C levels in the blood of mice in the HFD+Lf312 group and the Lf312 treatment group were significantly lower than those in the HFD group. In general, Lactobacillus fermentum HNU312 can significantly improve the blood lipid levels of mice, including TG, T-CHO and LDL-C, and reduce the risk of cardiovascular disease.
[0056] c. Lactobacillus fermentum HNU312 alleviated excessive fat accumulation in the liver and adipose tissue of mice fed a high-fat diet
[0057] Since elevated blood lipid levels were detected in the serum of mice fed a high-fat diet, we further performed histomorphometric analysis of the liver and adipose tissue. Obesity not only leads to enlargement of liver tissue and lipid accumulation, but also leads to enlargement of adipose tissue, including an increase in the number of adipocytes and an increase in the size of adipocytes. After 11 weeks of high-fat diet, the liver weight of mice in the HFD group increased significantly compared with the NFD group. The liver weight of mice in the HFD+Lf312 group, in which Lactobacillus fermentum HNU312 was added to the high-fat diet, was significantly lower than that of mice in the HFD group on a high-fat diet. In addition, the liver weights of the Lov-treated group and the Lf312-treated group were also significantly lower than those of mice in the HFD group. The results of Oil Red O staining showed that there was a large amount of fat stained red on the liver sections of mice in the HFD group, while less fat accumulation was observed in the NFD group, the Lov-treated group, and the Lf312-treated group. In addition, compared with the livers of mice in the HFD group, the lipid droplet accumulation levels in the liver tissues of the HFD+Lf312 group had obvious visual differences, so the fat accumulation was significantly improved. From the statistical results of the percentage of lipid droplets in liver tissue, the percentage of lipid droplets in the HFD+Lf312 group of mice was significantly lower than that in the HFD group, and the percentage of lipid droplets in the liver of mice in the NFD group, Lov treatment group and Lf312 treatment group was at a low level. In addition, the staining results of epididymal fat of mice showed that the fat cells of mice in the NFD group were neatly arranged and uniform in size. However, the fat cells of mice in the HFD group were significantly hypertrophic, and their morphology and size were seriously uneven. In the HFD+Lf312 group of mice supplemented with fermented Lactobacillus HNU312 in a high-fat diet, the fat tissue cells were significantly smaller than those in the HFD group, and the morphology and size were more uniform. The fat tissue cells in the Lov treatment group and the Lf312 treatment group were significantly smaller than those in the HFD group. In general, the addition of fermented Lactobacillus HNU312 to a high-fat diet can reduce the fat accumulation in liver tissue and adipose tissue caused by a high-fat diet, and after returning to a normal diet from a high-fat diet, the intake of fermented Lactobacillus HNU312 can significantly improve the fat accumulation.
[0058] Obviously, the above embodiments of the present invention are merely examples to more clearly illustrate the present invention, and are not limitations on the implementation methods of the present invention. For ordinary technicians in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is impossible to list all the implementation methods here. All obvious changes or modifications derived from the technical solution of the present invention are still within the protection scope of the present invention.
Claims
1. Fermented Lactobacillus mucilaginosus ( Limosilactobacillus fermentum ) Application of HNU312 in the preparation of lipid-lowering drugs, the lipid-lowering drugs include drugs for preventing and treating hyperlipidemia, the hyperlipidemia is hyperlipidemia caused by a high-fat diet, the lipid-lowering drugs include drugs for reducing body weight of humans or animals, the lipid-lowering drugs include drugs for reducing serum total cholesterol, serum triglycerides, and serum low-density lipoprotein in human or animal serum, the lipid-lowering drugs include drugs for reducing fat accumulation in liver tissue and adipose tissue caused by a high-fat diet, fermented Lactobacillus mucosa ( Limosilactobacillus fermentum ) HNU312 was deposited in the Guangdong Microbiological Culture Collection Center on September 16, 2022, with the deposit number GDMCC NO: 62803, and the deposit address is: Guangdong Microbiological Culture Collection Center, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou City, Guangdong Province, China.
